– Japan now offers ELEVIDYS gene therapy to children with Duchenne muscular dystrophy aged 3 years to less than 8 years – Company is eligible to receive...
Bio-Techne Corporation (NASDAQ: TECH) today announced that its Simple Western™ Technology played a key role in supporting the FDA approval of ZEVASKYN™ (prademagene zamikeracel), the first...
A new era of personalized gene therapy for Leukemia patients in Egypt, Saudi Arabia, and beyond. Porton Advanced Solutions, a global leading cell and gene therapy CDMO...
Data from longest and largest hemophilia gene therapy study demonstrates sustained factor VIII expression and bleed control, with 81.3% of individuals remaining off prophylaxis No...
AVB-101 Biomarker Data Readout Expected in 2026 Clinical Milestone Shared at AFTD Annual Caregiver Conference AviadoBio, a pioneering gene therapy company dedicated to developing and...